I-Mei (Emay) Siu
@imsmd
Followers
1K
Following
18K
Media
560
Statuses
3K
Senior Editor at Cancer Discovery @CD_AACR and cancer biologist (aka @[email protected]): views are most certainly my own
Baltimore, MD
Joined September 2008
👏🏻👏🏻👏🏻.
Thrilled to share that our new paper on Macrophage Migration Inhibitory Factor (MIF) as a key regulator of immune evasion in melanoma, is now published in @Cancer Discovery! Find the full study here:
0
0
0
RT @Satpathology: Our collaboration with @samuels_yardena and @NCIEytanRuppin is out in @CD_AACR ! . Why do genetically similar tumors show….
0
4
0
Jillian Phalen @hopkinskimmel presenting just-published work on DELFI (cell-free fragmentome/proteins) for the early detection of ovarian cancer #aacrLBx24
0
0
4
Excited to be here! If you’re here and want to ask about @CD_AACR, come join me for breakfast 🥞
Senior Editor I-Mei Sui, PhD is at the @AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation. #aacrLBx24 . Connect with her before or after the meeting to discuss your research and publishing opportunities! @imsmd
0
1
4
It’s the final day of @theNCI #RAS Initiative, and for the first time there is a pediatric cancer-focused session: there is a growing body of literature on Ras in pediatric cancer, as Elliot Steiglitz @UCSFCancer shows 👉🏻
aacrjournals.org
An open-label phase II trial of the MEK inhibitor trametinib in relapsed or refractory JMML resulted in an objective response rate of 50%, with 70% of patients either bridging to hematopoietic stem...
0
2
7
Andy Stephen @FredNatLab is speaking at @theNCI #RAS Initiative about the allosteric regulation of SOS, including the evaluation of the REM domain: since pictures are strictly forbidden, here is a completely accurate depiction of said domain 👉🏻
0
0
2
Robert Vonderheide @PennCancer suggests that KRAS inhibitors are immunotherapies and describes the work describing the effects of KRASi on the tumor immune contexture that Ben Stanger, he, and colleagues published last year 👉🏻
aacrjournals.org
Pharmacologic inhibition of KrasG12D in therapy-refractory models of pancreatic ductal adenocarcinoma promotes deep tumor regressions with alterations in the tumor microenvironment.
0
3
6
Mallika Singh of @Rev_Medicine is describing the strategy used to generate exciting pan-RAS RevMed inhibitors: check out the preclinical evaluation and characterization of RMC-6236 (includes patient data!) 👉🏻
aacrjournals.org
Broad-spectrum inhibition of RAS-GTP with RMC-6236 is active and tolerated at exposures that induce profound tumor regressions in preclinical models of RAS-driven cancers and that can be associated...
0
1
5
Andrew Aguirre discusses potential KRASi combinations with other modalities including immunotherapy for PDAC and cites a recent paper by @RonDePinho and colleagues as an example 👉🏻
0
4
8
Andrew Aguirre @DanaFarber is speaking about the identification of RAS G12C inhibitor resistance mechanisms at @theNCI #RAS Initiative Symposium, including work he and colleagues recently published 👉🏻
aacrjournals.org
Broad-spectrum inhibition of RAS-GTP with RMC-6236 is active and tolerated at exposures that induce profound tumor regressions in preclinical models of RAS-driven cancers and that can be associated...
0
2
10
The Fifth @theNCI #RAS Initiative Symposium (and my third!) is starting with @NCIDirector starting things off with her thoughts on the importance of the RAS Initiative in fostering collaborations/inspiration: also, she’s going to stay for the first day, so meet her if you can!
0
2
13
RT @ElizSMcKenna: Excited to attend the inaugural @AACR Grantee Summit to hear about the exciting work of AACR grantees and participate in….
0
1
0
RT @ManelEsteller: Thrilled to introduce "The Epigenetic Hallmarks of Cancer", our Cancer Discovery @CD_AACR @AACR article. A team work by….
0
102
0
RT @NCIDirector: I had the honor of presenting @NCIResearchCtr’s Dr. Steven Rosenberg with a milestone award for 50 years of excellent serv….
0
49
0
Amazing: 2 patients spontaneously shared their incredible journeys at @theNCI Clinical Center, one of whom was a patient of Steven Rosenberg, and @NCIDirector emphasized the crucial role of basic-clinical crosstalk in helping patients, as exemplified by Steven Rosenberg
0
2
6